Navigation Links
MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating,MacroVascular Outcomes Presented at the American Diabetes,Association 67th Scientific Sessions

CHICAGO, June 21, 2007 /PRNewswire/ --

What and When

Data from the PROactive and CHICAGO studies of ACTOS(R) (pioglitazone HCl) will be presented in poster format at the 67th Scientific Sessions of the American Diabetes Association in Chicago:

    -- Hospitalizations for serious adverse events in high-risk type 2

       diabetes patients treated with pioglitazone for 3 years: results from

       PROactive; Poster 0553-P presented on Saturday, June 23, from 12:30-

       2:30 p.m. and 6:00-7:15 p.m.

    -- The relationship between renal dysfunction and major cardiovascular

       outcomes in patients with diabetes: experience from PROactive; Poster

       0670-P presented on Saturday, June 23, from 12:30-2:30 p.m. and 6:00-

       7:15 p.m.

    -- Effects of pioglitazone in patients with type 2 diabetes and reduced

       glomerular filtration rate: an analysis from PROactive; Poster 0671-P

       presented on Saturday, June 23, from 12:30-2:30 p.m. and 6:00-7:15 p.m.

    -- Effects of long-term treatment with pioglitazone on lipid levels in

       patients receiving statin therapy at baseline in the PROactive study;

       Poster 0905-P presented on Sunday, June 24, from 12-2 p.m. and 6:15-

       7:30 p.m.

    -- Comparative effects of pioglitazone and glimepiride on lipoprotein

       subfractions: results from the CHICAGO Trial; Poster 0906-P presented

       on Sunday, June 24, from 12-2 p.m. and 6:15-7:30 p.m.

    -- Long-term cost-effectiveness analysis on ACTOS for the USA from

       PROactive; Poster 1209-P presented on Sunday, June 24, from 12-2 p.m.

       and 6:15-7:30 p.m.

About ACTOS

ACTOS works by directly targeting insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels. ACTOS is taken once daily as an adjunct to diet and exercise, and is approved for use for t ype 2 diabetes as monotherapy to lower blood glucose and in combination therapy with insulin, sulfonylureas or metformin.

Additional Information

ACTOS is not for everyone. ACTOS can cause fluid retention that may lead to or worsen heart failure, so tell your doctor if you have a history of these conditions. Talk to your doctor immediately if you experience rapid weight gain, fluid retention, or shortness of breath while taking ACTOS. If you have moderate to severe heart failure, ACTOS is not recommended. Your doctor should perform a blood test to check for liver problems before you start ACTOS and periodically thereafter.

Do not take ACTOS if you have active liver disease. Talk to your doctor immediately if you experience nausea, vomiting, stomach pain, tiredness, loss of appetite, dark urine, or yellowing of the skin. If you are of childbearing age, talk to your doctor before taking ACTOS as it could increase your chance of becoming pregnant. Some people taking ACTOS may experience flu-like symptoms, mild to moderate swelling of legs and ankles, and anemia. When taking ACTOS with insulin or sulfonylureas, you may be at risk for low blood sugar. Patients with diabetes should have regular eye exams. If you experience vision problems, consult your doctor immediately. Very rarely, some patients have experienced visual changes while taking ACTOS.

Please visit the ACTOS Web site at www.actos.com for Complete Prescribing Information.

Takeda Pharmaceuticals North America, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc., is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets oral products for diabetes, insomnia, wakefulness and gastroenterology. Through the Takeda Global Research & Development Center, Inc., the company has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit www.tpna.com.

ACTOS(R) (pioglitazone HCl) is a registered trademark of Takeda Pharmaceutical Company Limited and used under license by Takeda Pharmaceuticals North America, Inc.

North America, Inc.

CONTACT: Jocelyn M. Gerst of Takeda Global Research & Development,+1-224-554-5542, ; or Amy Losak of Ketchum, +1-646-935-3917,cell, +1-917-865-6688, , for Takeda PharmaceuticalsNorth America, Inc. jgerst@tgrd.com amy.losak@ketchum.com

Web site: http://www.tpna.com/http://www.actos.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
3. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
4. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
5. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
6. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
7. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
10. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... held the largest share in the ECG Cables And ... demand for remote monitoring ECG devices. On the other hand, ... to witness the highest growth rate during the forecast period. ... Dickinson and Company (U.S.), Medtronic plc ( Ireland ... and Mindray Medical International Limited ( China ), ...
(Date:12/2/2016)... , Dec 2, 2016 Research and Markets ... Share, Development, Growth and Demand Forecast to 2022" report to their ... , , ... $6 billion in 2015, and it is expected to grow at a ... is expected to witness faster growth during the forecast period, a CAGR ...
(Date:12/2/2016)... SAN FRANCISCO , Dec. 2, 2016  PipelineRx, ... clinical telepharmacy, will be offering demonstrations of its ... American Society of Health-System Pharmacists 2016 Midyear Clinical ... Las Vegas . With nearly 300 hospital ... telepharmacy services and technology designed to dramatically improve ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 2016 , ... On Dec. 2, 2016, CURE® magazine will host the 4th ... 2016 MPN Heroes—eight individuals who have made a difference in the field of rare ... of care, demonstrating leadership within the MPN community and/or a commitment to individual patients. ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change ... Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch ... plan (Part D) need to make changes during this period order for their new ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, ... standing as living proof that attitude and determination can combine into the most ... spike around the holidays. This campaign will offer patients a new-found hope, by ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
Breaking Medicine News(10 mins):